Vineet Laboratories Ltd
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
- Market Cap ₹ 28.1 Cr.
- Current Price ₹ 30.5
- High / Low ₹ 78.5 / 25.4
- Stock P/E
- Book Value ₹ 15.0
- Dividend Yield 0.00 %
- ROCE -25.1 %
- ROE -81.8 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -6.59%
- Promoter holding is low: 29.3%
- Company has a low return on equity of -19.6% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|
0 | 243 | 191 | 212 | 151 | 75 | 59 | |
0 | 235 | 178 | 205 | 143 | 91 | 74 | |
Operating Profit | -0 | 8 | 13 | 8 | 7 | -16 | -15 |
OPM % | 3% | 7% | 4% | 5% | -22% | -26% | |
0 | 0 | 0 | 0 | 0 | 2 | 2 | |
Interest | 0 | 3 | 2 | 3 | 5 | 4 | 3 |
Depreciation | 0 | 2 | 2 | 2 | 3 | 2 | 3 |
Profit before tax | -0 | 4 | 9 | 2 | 0 | -21 | -20 |
Tax % | 0% | 56% | 29% | 38% | -183% | -3% | |
-0 | 2 | 7 | 1 | 1 | -20 | -19 | |
EPS in Rs | -0.24 | 1.93 | 7.20 | 1.36 | 1.12 | -21.90 | -20.54 |
Dividend Payout % | 0% | 0% | 14% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -27% |
TTM: | -57% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -13629% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -23% |
1 Year: | -54% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -7% |
3 Years: | -20% |
Last Year: | -82% |
Balance Sheet
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Equity Capital | 0.41 | 9 | 9 | 9 | 9 | 9 |
Reserves | -0 | 17 | 24 | 24 | 26 | 5 |
0 | 12 | 27 | 31 | 44 | 40 | |
0 | 70 | 74 | 51 | 38 | 40 | |
Total Liabilities | 0 | 109 | 133 | 116 | 117 | 95 |
0 | 20 | 21 | 27 | 27 | 25 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 |
0 | 89 | 112 | 89 | 90 | 69 | |
Total Assets | 0 | 109 | 133 | 116 | 117 | 95 |
Cash Flows
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
0 | 27 | 8 | -10 | -11 | 11 | |
0 | -8 | -4 | -7 | 0 | -3 | |
0 | 19 | 12 | 0 | 11 | -8 | |
Net Cash Flow | 0 | 38 | 16 | -16 | -0 | 0 |
Ratios
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Debtor Days | 64 | 69 | 60 | 77 | 64 | |
Inventory Days | 73 | 109 | 98 | 158 | 260 | |
Days Payable | 114 | 161 | 74 | 103 | 175 | |
Cash Conversion Cycle | 23 | 17 | 84 | 131 | 150 | |
Working Capital Days | 14 | -19 | 21 | 28 | -37 | |
ROCE % | 34% | 23% | 9% | 7% | -25% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
25 Jul - Newspaper advertisements in Financial Express (English Language) and Nava Telangana (Telugu Language) regarding the Unaudited standalone Financial results of the company for the first quarter …
-
Disclosure Under Regulation 7(2) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015 - Mr. V Varprasada Rao , Promoter
24 Jul - Promoter Valluru Vara Prasad Rao sold shares reducing holding from 0.20% to 0.15% in July 2025.
- Unaudited Standalone Financial Results 22 Jul
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday, July 22, 2025 As Required Under Regulation 30 Of SEBI (LODR) Regulations, 2015
22 Jul - Q1 FY26 unaudited results: INR 1,122.43 lakh loss before tax, detailed financials and auditor review.
-
Board Meeting Intimation for Considering The Unaudited Standalone Financial Results Of The Company For The First Quarter Ended On June 30, 2025 Along With The Limited Review Report.
15 Jul - Board meeting on July 22 to approve Q1 June 2025 financial results; trading window closed till July 24.
Product Profile:
a) API Intermediates:[1] Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine
b) Fine Chemicals and Reagents:[2] IPTG, PNPP, X-Gal, ATCA, Butyl Lithium, Furaldehyde, Butylnitrite, Aminouracil, etc.